Summary

According to Triton’s research report, the Asia-Pacific surgical site infection control market is expected to advance at a CAGR of 6.14% over the forecast years 2024-2032.
The surgical site infection control market in the Asia-Pacific region is witnessing significant growth, driven by increasing healthcare expenditures and rising awareness of infection control practices. The World Health Organization (WHO) has emphasized the critical need for improved infection prevention and control (IPC), noting that surgical site infections are among the most common healthcare-associated infections, with an estimated 11% of surgical patients affected in low- and middle-income countries. This has prompted healthcare facilities to adopt stricter infection control protocols, further spurred by government initiatives aimed at reducing healthcare-associated infections.
The countries evaluated in this region comprise China, ASEAN Countries, Japan, India, South Korea, Australia & New Zealand, and Rest of Asia-Pacific.
China spearheads the regional market, attaining around $325.1 million in 2023
• In China, surgical site infections are notably prevalent, with several studies conducted to determine their incidence. One comprehensive study reported an overall SSI rate of around 4.7% across various departments, including internal medicine, oncology, neurology, and obstetrics.
• The government has been proactive in addressing the issue of surgical site infections through stringent regulatory frameworks and national guidelines. For instance, the National Health Commission of China has implemented several infection prevention and control (IPC) programs aimed at reducing the incidence of SSIs. These programs are part of broader initiatives to enhance patient safety and improve the quality of healthcare services.
• These developments align with the Health China 2030 initiative, which emphasizes the need for improved health outcomes through better healthcare services and infection control.
Market Forecast for India
In India, public hospitals face inadequate administrative and financial support, hindering comprehensive infection control programs. This leads to extremely low nurse-to-patient ratios, particularly in intensive care units, where high HAI rates and overcrowding are common. Several factors, including an aging population, contaminated wounds, prolonged surgeries, the use of drains, and extended hospital stays, contribute to a higher incidence of surgical site infections (SSI). These growing challenges, coupled with an increase in surgical procedures and the expanding elderly population, are expected to drive demand for effective surgical site infection management across India.
The market is segmented based on industry vertical, procedure, type of infection, and product. The industry vertical segment includes ambulatory surgical centers and hospitals.
Ambulatory care refers to medical services provided in facilities where patients do not stay overnight, such as outpatient clinics, physicians’ offices, urgent care centers, and rehabilitation centers. Healthcare-associated infections remain a common complication after ambulatory surgeries. However, most of these infections are preventable due to stringent regulations that ensure ambulatory surgical centers (ASCs) maintain the same high safety standards as hospitals. Advances in technology, anesthesia, and minimally invasive procedures have made surgeries at ASCs safer.
Contender Analysis in the Surgical Site Infection Control Market:
Johnson & Johnson, based in the United States, is involved in the research, development, manufacturing, and marketing of personal care products, pharmaceuticals, and surgical equipment. The company operates through three main segments: medical devices, pharmaceuticals, and consumer health. The medical devices segment supplies products to wholesalers, retailers, and hospitals, primarily used by healthcare professionals in various settings. These products address needs in orthopedics, cancer treatment, cardiovascular care, etc. Founded in 1886, Johnson & Johnson serves clients across varied regions, including Asia-Pacific.
In May 2024, Ethicon, a Johnson & Johnson MedTech company, launched the ECHELON LINEAR™ Cutter. This device integrates 3D-Stapling Technology and Gripping Surface Technology (GST) that reduces staple line leaks by 47%, reducing surgical risks.
Other notable companies offering solutions in the market include Sotera Health LLC, Steris Corporation, Stryker Corporation, and Kimberly-Clark Corporation.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1. ASIA-PACIFIC SURGICAL SITE INFECTION CONTROL MARKET - SUMMARY
2. INDUSTRY OUTLOOK
2.1. IMPACT ANALYSIS ON THE SURGICAL SITE INFECTION CONTROL MARKET
2.1.1. COVID-19 IMPACT
2.2. PORTER’S FIVE FORCES ANALYSIS
2.2.1. THREAT OF NEW ENTRANTS
2.2.2. THREAT OF SUBSTITUTES
2.2.3. BARGAINING POWER OF BUYERS
2.2.4. BARGAINING POWER OF SUPPLIERS
2.2.5. THREAT OF COMPETITIVE RIVALRY
2.3. KEY MARKET STRATEGIES
2.3.1. PRODUCT LAUNCHES
2.3.2. ACQUISITIONS
2.3.3. BUSINESS DIVESTITURES & EXPANSIONS
2.4. MARKET DRIVERS
2.4.1. ESCALATING INCIDENCE OF HOSPITAL-ACQUIRED INFECTIONS
2.4.2. GROWING GERIATRIC POPULATION
2.4.3. REGULATORY GUIDELINES FOR PREVENTING HOSPITAL-ACQUIRED INFECTION
2.5. MARKET CHALLENGES
2.5.1. INCREASE IN OUTPATIENT TREATMENT
2.5.2. SURGE IN MEDICAL WASTE DUE TO THE USE OF DISPOSABLE MEDICAL ITEMS
2.5.3. INSUFFICIENT AWARENESS REGARDING HOSPITAL-ACQUIRED INFECTIONS
2.6. MARKET OPPORTUNITIES
2.6.1. GROWTH OF MINIMALLY INVASIVE AND OUTPATIENT SURGICAL PRACTICES
2.6.2. RISE IN SURGICAL PROCEDURE RATES
2.6.3. TECHNOLOGICAL ADVANCEMENTS IN PREVENTING SURGICAL SITE INFECTIONS
2.7. ANALYST PERSPECTIVE
3. ASIA-PACIFIC SURGICAL SITE INFECTION CONTROL MARKET – BY PROCEDURE
3.1. LAPAROSCOPY
3.2. ORTHOPEDIC SURGERY
3.3. CARDIOVASCULAR
3.4. OBSTETRICS AND GYNECOLOGY
3.5. WOUND CLOSURE
3.6. PLASTIC & RECONSTRUCTIVE SURGERY
3.7. THORACIC SURGERY
3.8. MICROVASCULAR
3.9. UROLOGY
3.10. NEUROSURGERY
3.11. OTHER PROCEDURES
4. ASIA-PACIFIC SURGICAL SITE INFECTION CONTROL MARKET – BY TYPE OF INFECTION
4.1. SUPERFICIAL INCISIONAL SSI
4.2. DEEP INCISIONAL SSI
4.3. ORGAN OR SPACE SSI
5. ASIA-PACIFIC SURGICAL SITE INFECTION CONTROL MARKET – BY INDUSTRY VERTICAL
5.1. HOSPITALS
5.2. AMBULATORY SURGICAL CENTERS
6. ASIA-PACIFIC SURGICAL SITE INFECTION CONTROL MARKET – BY PRODUCT
6.1. DISINFECTANTS
6.1.1. SKIN DISINFECTANTS
6.1.2. HAND DISINFECTANTS
6.2. MANUAL REPROCESSORS SOLUTIONS
6.3. SURGICAL DRAPES
6.4. SURGICAL GLOVES
6.5. SKIN PREPARATION SOLUTIONS
6.6. SURGICAL IRRIGATION
6.7. SURGICAL SCRUBS
6.8. HAIR CLIPPERS
6.9. MEDICAL NONWOVENS
6.10. OTHER PRODUCTS
7. ASIA-PACIFIC SURGICAL SITE INFECTION CONTROL MARKET – BY COUNTRY OUTLOOK
7.1. ASIA-PACIFIC
7.1.1. COUNTRY ANALYSIS
7.1.1.1. CHINA
7.1.1.1.1. CHINA SURGICAL SITE INFECTION CONTROL MARKET FORECAST & PROSPECTS
7.1.1.2. JAPAN
7.1.1.2.1. JAPAN SURGICAL SITE INFECTION CONTROL MARKET FORECAST & PROSPECTS
7.1.1.3. INDIA
7.1.1.3.1. INDIA SURGICAL SITE INFECTION CONTROL MARKET FORECAST & PROSPECTS
7.1.1.4. SOUTH KOREA
7.1.1.4.1. SOUTH KOREA SURGICAL SITE INFECTION CONTROL MARKET FORECAST & PROSPECTS
7.1.1.5. ASEAN COUNTRIES
7.1.1.5.1. ASEAN COUNTRIES SURGICAL SITE INFECTION CONTROL MARKET FORECAST & PROSPECTS
7.1.1.6. AUSTRALIA & NEW ZEALAND
7.1.1.6.1. AUSTRALIA & NEW ZEALAND SURGICAL SITE INFECTION CONTROL MARKET FORECAST & PROSPECTS
7.1.1.7. REST OF ASIA-PACIFIC
7.1.1.7.1. REST OF ASIA-PACIFIC SURGICAL SITE INFECTION CONTROL MARKET FORECAST & PROSPECTS
8. COMPETITIVE LANDSCAPE
8.1. AMERICAN POLYFILM INC
8.1.1. OVERVIEW
8.1.2. PORTFOLIO
8.1.3. KEY STRENGTHS
8.1.4. KEY CHALLENGES
8.2. 3M
8.2.1. OVERVIEW
8.2.2. PORTFOLIO
8.2.3. KEY STRENGTHS
8.2.4. KEY CHALLENGES
8.3. ANSELL LIMITED
8.3.1. OVERVIEW
8.3.2. PORTFOLIO
8.3.3. KEY STRENGTHS
8.3.4. KEY CHALLENGES
8.4. BELIMED LIFE SCIENCE AG
8.4.1. OVERVIEW
8.4.2. PORTFOLIO
8.4.3. KEY STRENGTHS
8.4.4. KEY CHALLENGES
8.5. BECTON, DICKINSON AND COMPANY (BD)
8.5.1. OVERVIEW
8.5.2. PORTFOLIO
8.5.3. KEY STRENGTHS
8.5.4. KEY CHALLENGES
8.6. BIOMERIEUX SA
8.6.1. OVERVIEW
8.6.2. PORTFOLIO
8.6.3. KEY STRENGTHS
8.6.4. KEY CHALLENGES
8.7. GETINGE AB
8.7.1. OVERVIEW
8.7.2. PORTFOLIO
8.7.3. KEY STRENGTHS
8.7.4. KEY CHALLENGES
8.8. GAMA HEALTHCARE
8.8.1. OVERVIEW
8.8.2. PORTFOLIO
8.8.3. KEY STRENGTHS
8.8.4. KEY CHALLENGES
8.9. JOHNSON & JOHNSON
8.9.1. OVERVIEW
8.9.2. PORTFOLIO
8.9.3. KEY STRENGTHS
8.9.4. KEY CHALLENGES
8.10. SOTERA HEALTH LLC
8.10.1. OVERVIEW
8.10.2. PORTFOLIO
8.10.3. KEY STRENGTHS
8.10.4. KEY CHALLENGES
8.11. KIMBERLY-CLARK CORPORATION
8.11.1. OVERVIEW
8.11.2. PORTFOLIO
8.11.3. KEY STRENGTHS
8.11.4. KEY CHALLENGES
8.12. STERIS CORPORATION
8.12.1. OVERVIEW
8.12.2. PORTFOLIO
8.12.3. KEY STRENGTHS
8.12.4. KEY CHALLENGES
8.13. STRYKER CORPORATION
8.13.1. OVERVIEW
8.13.2. PORTFOLIO
8.13.3. KEY STRENGTHS
8.13.4. KEY CHALLENGES
9. RESEARCH METHODOLOGY & SCOPE
9.1. RESEARCH SCOPE & DELIVERABLES
9.2. SOURCES OF DATA
9.3. RESEARCH METHODOLOGY


LIST OF TABLES
TABLE 1: ASIA-PACIFIC SURGICAL SITE INFECTION CONTROL MARKET, BY COUNTRY OUTLOOK, 2024-2032 (IN $ MILLION)
TABLE 2: LIST OF PRODUCT LAUNCHES
TABLE 3: LIST OF ACQUISITIONS
TABLE 4: LIST OF BUSINESS DIVESTITURES & EXPANSIONS
TABLE 5: ASIA-PACIFIC SURGICAL SITE INFECTION CONTROL MARKET, BY PROCEDURE, 2024-2032 (IN $ MILLION)
TABLE 6: ASIA-PACIFIC SURGICAL SITE INFECTION CONTROL MARKET, BY TYPE OF INFECTION, 2024-2032 (IN $ MILLION)
TABLE 7: ASIA-PACIFIC SURGICAL SITE INFECTION CONTROL MARKET, BY INDUSTRY VERTICAL, 2024-2032 (IN $ MILLION)
TABLE 8: ASIA-PACIFIC SURGICAL SITE INFECTION CONTROL MARKET, BY PRODUCT, 2024-2032 (IN $ MILLION)
TABLE 9: ASIA-PACIFIC SURGICAL SITE INFECTION CONTROL MARKET, BY COUNTRY OUTLOOK, 2024-2032 (IN $ MILLION)


LIST OF FIGURES
FIGURE 1: PORTER’S FIVE FORCES ANALYSIS
FIGURE 2: ASIA-PACIFIC SURGICAL SITE INFECTION CONTROL MARKET, BY PROCEDURE, 2023 & 2032 (IN %)
FIGURE 3: ASIA-PACIFIC SURGICAL SITE INFECTION CONTROL MARKET, BY LAPAROSCOPY, 2024-2032 (IN $ MILLION)
FIGURE 4: ASIA-PACIFIC SURGICAL SITE INFECTION CONTROL MARKET, BY ORTHOPEDIC SURGERY, 2024-2032 (IN $ MILLION)
FIGURE 5: ASIA-PACIFIC SURGICAL SITE INFECTION CONTROL MARKET, BY CARDIOVASCULAR, 2024-2032 (IN $ MILLION)
FIGURE 6: ASIA-PACIFIC SURGICAL SITE INFECTION CONTROL MARKET, BY OBSTETRICS AND GYNECOLOGY, 2024-2032 (IN $ MILLION)
FIGURE 7: ASIA-PACIFIC SURGICAL SITE INFECTION CONTROL MARKET, BY WOUND CLOSURE, 2024-2032 (IN $ MILLION)
FIGURE 8: ASIA-PACIFIC SURGICAL SITE INFECTION CONTROL MARKET, BY PLASTIC & RECONSTRUCTIVE SURGERY, 2024-2032 (IN $ MILLION)
FIGURE 9: ASIA-PACIFIC SURGICAL SITE INFECTION CONTROL MARKET, BY THORACIC SURGERY, 2024-2032 (IN $ MILLION)
FIGURE 10: ASIA-PACIFIC SURGICAL SITE INFECTION CONTROL MARKET, BY MICROVASCULAR, 2024-2032 (IN $ MILLION)
FIGURE 11: ASIA-PACIFIC SURGICAL SITE INFECTION CONTROL MARKET, BY UROLOGY, 2024-2032 (IN $ MILLION)
FIGURE 12: ASIA-PACIFIC SURGICAL SITE INFECTION CONTROL MARKET, BY NEUROSURGERY, 2024-2032 (IN $ MILLION)
FIGURE 13: ASIA-PACIFIC SURGICAL SITE INFECTION CONTROL MARKET, BY OTHER PROCEDURES, 2024-2032 (IN $ MILLION)
FIGURE 14: ASIA-PACIFIC SURGICAL SITE INFECTION CONTROL MARKET, BY TYPE OF INFECTION, 2023 & 2032 (IN %)
FIGURE 15: ASIA-PACIFIC SURGICAL SITE INFECTION CONTROL MARKET, BY SUPERFICIAL INCISIONAL SSI, 2024-2032 (IN $ MILLION)
FIGURE 16: ASIA-PACIFIC SURGICAL SITE INFECTION CONTROL MARKET, BY DEEP INCISIONAL SSI, 2024-2032 (IN $ MILLION)
FIGURE 17: ASIA-PACIFIC SURGICAL SITE INFECTION CONTROL MARKET, BY ORGAN OR SPACE SSI, 2024-2032 (IN $ MILLION)
FIGURE 18: ASIA-PACIFIC SURGICAL SITE INFECTION CONTROL MARKET, BY INDUSTRY VERTICAL, 2023 & 2032 (IN %)
FIGURE 19: ASIA-PACIFIC SURGICAL SITE INFECTION CONTROL MARKET, BY HOSPITALS, 2024-2032 (IN $ MILLION)
FIGURE 20: ASIA-PACIFIC SURGICAL SITE INFECTION CONTROL MARKET, BY AMBULATORY SURGICAL CENTERS, 2024-2032 (IN $ MILLION)
FIGURE 21: ASIA-PACIFIC SURGICAL SITE INFECTION CONTROL MARKET, BY PRODUCT, 2023 & 2032 (IN %)
FIGURE 22: ASIA-PACIFIC SURGICAL SITE INFECTION CONTROL MARKET, BY DISINFECTANTS, 2024-2032 (IN $ MILLION)
FIGURE 23: ASIA-PACIFIC SURGICAL SITE INFECTION CONTROL MARKET, BY DISINFECTANTS, 2023 & 2032 (IN %)
FIGURE 24: ASIA-PACIFIC SURGICAL SITE INFECTION CONTROL MARKET, BY SKIN DISINFECTANTS, 2024-2032 (IN $ MILLION)
FIGURE 25: ASIA-PACIFIC SURGICAL SITE INFECTION CONTROL MARKET, BY HAND DISINFECTANTS, 2024-2032 (IN $ MILLION)
FIGURE 26: ASIA-PACIFIC SURGICAL SITE INFECTION CONTROL MARKET, BY MANUAL REPROCESSORS SOLUTIONS, 2024-2032 (IN $ MILLION)
FIGURE 27: ASIA-PACIFIC SURGICAL SITE INFECTION CONTROL MARKET, BY SURGICAL DRAPES, 2024-2032 (IN $ MILLION)
FIGURE 28: ASIA-PACIFIC SURGICAL SITE INFECTION CONTROL MARKET, BY SURGICAL GLOVES, 2024-2032 (IN $ MILLION)
FIGURE 29: ASIA-PACIFIC SURGICAL SITE INFECTION CONTROL MARKET, BY SKIN PREPARATION SOLUTIONS, 2024-2032 (IN $ MILLION)
FIGURE 30: ASIA-PACIFIC SURGICAL SITE INFECTION CONTROL MARKET, BY SURGICAL IRRIGATION, 2024-2032 (IN $ MILLION)
FIGURE 31: ASIA-PACIFIC SURGICAL SITE INFECTION CONTROL MARKET, BY SURGICAL SCRUBS, 2024-2032 (IN $ MILLION)
FIGURE 32: ASIA-PACIFIC SURGICAL SITE INFECTION CONTROL MARKET, BY HAIR CLIPPERS, 2024-2032 (IN $ MILLION)
FIGURE 33: ASIA-PACIFIC SURGICAL SITE INFECTION CONTROL MARKET, BY MEDICAL NONWOVENS, 2024-2032 (IN $ MILLION)
FIGURE 34: ASIA-PACIFIC SURGICAL SITE INFECTION CONTROL MARKET, BY OTHER PRODUCTS, 2024-2032 (IN $ MILLION)
FIGURE 35: ASIA-PACIFIC SURGICAL SITE INFECTION CONTROL MARKET, BY COUNTRY OUTLOOK, 2023 & 2032 (IN %)
FIGURE 36: CHINA SURGICAL SITE INFECTION CONTROL MARKET 2024-2032 (IN $ MILLION)
FIGURE 37: JAPAN SURGICAL SITE INFECTION CONTROL MARKET 2024-2032 (IN $ MILLION)
FIGURE 38: INDIA SURGICAL SITE INFECTION CONTROL MARKET 2024-2032 (IN $ MILLION)
FIGURE 39: SOUTH KOREA SURGICAL SITE INFECTION CONTROL MARKET 2024-2032 (IN $ MILLION)
FIGURE 40: ASEAN COUNTRIES SURGICAL SITE INFECTION CONTROL MARKET 2024-2032 (IN $ MILLION)
FIGURE 41: AUSTRALIA & NEW ZEALAND SURGICAL SITE INFECTION CONTROL MARKET 2024-2032 (IN $ MILLION)
FIGURE 42: REST OF ASIA-PACIFIC SURGICAL SITE INFECTION CONTROL MARKET 2024-2032 (IN $ MILLION)